Study demonstrates use of Parsortix to assess PD-L1 Status of CTCs in Non-Small Cell Lung Cancer patients with a simple blood test Further evidence supporting ANGLE's decision to develop a ...
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results